Somatostatin receptor expression in Hurthle cell cancer of the thyroid

Seza A. Gulec, Aldo N Serafini, Kasi S. Sridhar, Kamil R. Peker, Anurag Gupta, W. Jarrard Goodwin, George N Sfakianakis, Frederick L Moffat

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.

Original languageEnglish
Pages (from-to)243-245
Number of pages3
JournalJournal of Nuclear Medicine
Volume39
Issue number2
StatePublished - Feb 1 1998

Fingerprint

Somatostatin Receptors
Oxyphil Cells
Nuclear Medicine
Somatostatin
Neoplasms
Hurthle cell Thyroid cancer
Therapeutics
pentetreotide

Keywords

  • Hurthle cell cancer
  • Indium-111- pentetreotide
  • Somatostatin receptors
  • Thyroid cancer

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Somatostatin receptor expression in Hurthle cell cancer of the thyroid. / Gulec, Seza A.; Serafini, Aldo N; Sridhar, Kasi S.; Peker, Kamil R.; Gupta, Anurag; Goodwin, W. Jarrard; Sfakianakis, George N; Moffat, Frederick L.

In: Journal of Nuclear Medicine, Vol. 39, No. 2, 01.02.1998, p. 243-245.

Research output: Contribution to journalArticle

Gulec, SA, Serafini, AN, Sridhar, KS, Peker, KR, Gupta, A, Goodwin, WJ, Sfakianakis, GN & Moffat, FL 1998, 'Somatostatin receptor expression in Hurthle cell cancer of the thyroid', Journal of Nuclear Medicine, vol. 39, no. 2, pp. 243-245.
Gulec, Seza A. ; Serafini, Aldo N ; Sridhar, Kasi S. ; Peker, Kamil R. ; Gupta, Anurag ; Goodwin, W. Jarrard ; Sfakianakis, George N ; Moffat, Frederick L. / Somatostatin receptor expression in Hurthle cell cancer of the thyroid. In: Journal of Nuclear Medicine. 1998 ; Vol. 39, No. 2. pp. 243-245.
@article{52c8a1148c8e45ee875f80f6a6a31360,
title = "Somatostatin receptor expression in Hurthle cell cancer of the thyroid",
abstract = "Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.",
keywords = "Hurthle cell cancer, Indium-111- pentetreotide, Somatostatin receptors, Thyroid cancer",
author = "Gulec, {Seza A.} and Serafini, {Aldo N} and Sridhar, {Kasi S.} and Peker, {Kamil R.} and Anurag Gupta and Goodwin, {W. Jarrard} and Sfakianakis, {George N} and Moffat, {Frederick L}",
year = "1998",
month = "2",
day = "1",
language = "English",
volume = "39",
pages = "243--245",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "2",

}

TY - JOUR

T1 - Somatostatin receptor expression in Hurthle cell cancer of the thyroid

AU - Gulec, Seza A.

AU - Serafini, Aldo N

AU - Sridhar, Kasi S.

AU - Peker, Kamil R.

AU - Gupta, Anurag

AU - Goodwin, W. Jarrard

AU - Sfakianakis, George N

AU - Moffat, Frederick L

PY - 1998/2/1

Y1 - 1998/2/1

N2 - Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.

AB - Somatostatin receptor expression, which was not a previously described marker for Hurthle cell cancer of the thyroid, was demonstrated by in vivo imaging with 111In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hurthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.

KW - Hurthle cell cancer

KW - Indium-111- pentetreotide

KW - Somatostatin receptors

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=0031916461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031916461&partnerID=8YFLogxK

M3 - Article

C2 - 9476928

AN - SCOPUS:0031916461

VL - 39

SP - 243

EP - 245

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 2

ER -